Bolton Medical Announces The First Patient Treated With The New TREO Abdominal Stent-Graft System

SUNRISE, Fla., Oct. 16, 2015 /PRNewswire/ -- Bolton Medical, a subsidiary of the WerfenLife Company, announced the first commercial implant of the TREO Abdominal Stent-Graft System by Professor Giovanni Torsello, MD, Director of the Center for Vascular and Endovascular Surgery at St. Franciscus Hospital Muenster in Munster, Germany.  

Bolton Medical began a limited market release of TREO involving selected customers in Europe with plans of a full launch at the Leipzig Interventional Course in January 2016.

The TREO Abdominal Stent-Graft System was engineered to optimize patient applicability for Endovascular Aneurysm Repair (EVAR) with design elements focused on the long-term stability of the implant even in the most challenging anatomies.  The dual proximal fixation provides increased resistance to migration forces.  In addition, TREO's Lock Stent technology provides active fixation between the modular components and is the only of its kind on the market.

"We believe that the more control we can give the physicians during the planning and implant of an AAA repair, the better the outcomes will be for the patient, both acutely and in the long term," said Scott Rush, Vice President of Research & Development.

The TREO system has a tri-modular design with a wide range of sizes across all components, and it allows for precise and controlled deployment, with the ability to reposition the stent-graft during the procedure.

"TREO tracked beautifully through the patient's anatomy," said Professor Giovanni Torsello, MD, St. Franciscus Hospital Muenster.  "I had complete deployment control as I was able to make adjustments cranially and caudally prior to final placement. The case was successful at final imaging."

During TREO's limited market release, Bolton will continue to engage selected European physicians as they prepare for the full launch in January.

"We are looking forward to sharing the TREO technology worldwide," said  Paul Kuznik, Chief Executive Officer.  "The technology showcased in TREO is very unique, as it was designed to optimize every aspect of the procedure.  We firmly believe that this technology will be highly competitive in the global EVAR market."

TREO is the latest addition to the Bolton Medical's abdominal product portfolio.  Additional product information is available at www.boltonmedical.com.

About Bolton Medical
Bolton Medical is a subsidiary of the WerfenLife Company.  WerfenLife is a global company that manufactures and distributes medical diagnostic solutions and medical devices worldwide.  Headquartered in the U.S., Bolton Medical improves the quality of patient care by developing, manufacturing, and distributing innovative, high-quality products and technology solely focused on the aorta. 

CONTACT:         

Megan Eckerman
Vice President of Marketing
+1 954.838.9699 
meckerman@boltonmedical.com 

Latoya Spencer
Marketing Communications
+1 786.510.6425 
lspencer@boltonmedical.com  

Photo - http://photos.prnewswire.com/prnh/20151016/277811

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bolton-medical-announces-the-first-patient-treated-with-the-new-treo-abdominal-stent-graft-system-300161378.html

SOURCE Bolton Medical